Why the study?
Does intravenous amiodarone terminate and prevent recurrences of sustained ventricular tachycardia and ventricular fibrillation in patients with organic heart disease and depressed left ventricular function?
Does intravenous amiodarone terminate and prevent recurrences of sustained ventricular tachycardia and ventricular fibrillation in patients with organic heart disease and depressed left ventricular function?
Intravenous amiodarone is effective for the short-term termination and prevention of refractory sustained ventricular tachycardia and ventricular fibrillation in patients with depressed left ventricular function.
Answers are grounded in this paper and cite their sources.
May support short-term IV amiodarone for refractory VT/VF in low LVEF; hypothesis-generating case data requiring randomized confirmation.
The clinical efficacy of intravenous amiodarone in terminating sustained ventricular tachycardia and in preventing recurrences of ventricular tachycardia and ventricular fibrillation was evaluated in 26 patients. All of them presented with organic heart disease accompanied by depressed left ventricular function. Intravenous amiodarone terminated spontaneous ventricular tachycardia in eight of 19 patients. Fifteen of the 26 patients had had at least one episode of ventricular tachycardia or ventricular fibrillation each day in the period immediately before the intravenous administration of amiodarone. Amiodarone controlled ventricular tachycardia or ventricular fibrillation in nine of these 15 patients; in three further cases it was successful when supplemented by additional administration of a previously ineffective antiarrhythmic drug and ventricular pacing. Two patients died despite these measures. In one, the amiodarone infusion had to be stopped because of an arrhythmogenic effect. Sustained deterioration of haemodynamic function or of pre-existing intraventricular conduction disturbances was never seen. Intravenous amiodarone was effective in terminating sustained ventricular tachycardia and in preventing frequent episodes of ventricular arrhythmia that were refractory to other antiarrhythmic drugs.
No takes yet. Share an insight, caveat, or question.
Schützenberger et al. (1989) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: